The present invention discloses a novel therapeutic agent for prevention and treatment of Parkinsons disease. The novel agent is a known compound Pyrroloquinoline Quinone or PQQ, whose potential use specifically for the prevention and treatment of Parkinsons disease has not been described earlier. Main use has been as a research compound or dietary supplement with beneficial health effects. The present invention provides supporting scientific evidence relating to its efficacy in the treatment of Parkinsons disease without any side-effects. The invention also provides appropriate therapeutic dosage for treatment of Parkinsons disease and route of administration of the agent. 10mg/kg dose of PQQ i.p. (Intraperitoneal) in mice showed significant and dose dependent amelioration of oxidative stress by decreasing Thiobarbituric acid reactive substances (TBARS) and myeloperoxidase levels and increasing the levels of reduced glutathione and catalase compared to control group. The dose can easily be extrapolated to effective therapeutic dose in humans.
Thakur Gurjeet Singh, Sonia Dhiman, Avneesh Singh, Paramdeep Singh, Mayank Sippy